Development of dipeptidyl peptidase-4 inhibitors Essays

pharmaceutical ingredients: 1. Sitagliptin: Sitagliptin is an orally-active inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme. Inhibition of DPP-4 prevents breakdown of GLP-1and GIP and allows for an extended stimulation of insulin secretion, along with inhibition of glucagon secretion. This drives overall blood glucose towards a normal value. IUPAC name: (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H- [1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one;phosphoric

Critical Thinking Prescription Assignment #4 Mr. Griffin is a 55-year-old African-American male recently diagnosed with type II diabetes, which is characterized by, “insulin resistance and β-cell dysfunction” (Edmunds & Mayhew, 2013, p. 590). Mr. Griffin’s hemoglobin A1C is 9.6% and glucose level is 353. According to the American Diabetes Association (ADA) (as cited in ClinicalKey, 2008), diabetes is defined by, “glycosylated hemoglobin (HbA1c) ≥6.5%, a fasting plasma glucose level ≥126 mg/dL,